ZYBERNO
Stock Report
Updated Jun 7, 2026

NewcelX Ltd. (NLSP)

Healthcare • NASDAQ

$2.74

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
8.0/100
POOR BUSINESS
NewcelX Ltd. (NLSP) scores 8/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.09x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-35.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

NewcelX Ltd. (NLSP) stock report — Zyberno Score 8/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.74
Market Cap:$10.53M

Valuation Multiples (2)

P/B Ratio:1.45x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$8.69M
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:91.3%
Fundamental Growth Rate (g):-32.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:19.7%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.76x
Quick Ratio:0.76x
Cash Ratio:0.52x

Leverage Analysis (3)

Debt To Equity Ttm:0.09x
Debt-to-Equity Ratio:0.09x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-6,654.55x
Times Interest Earned:-6,654.55

Capital Structure (4)

Working Capital:-1,013,000.00
Cash And Cash Equivalents:2,201,000.00
Long Term Debt:$0.00
Net Debt:-$1.85M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$2.56M

Bottom Line Performance (3)

-$8.30M
Income Before Tax:-$7.20M
Ebitda Ttm:-2,507,000.00

Operating Expenses (5)

Operating Expenses:10,000,000.00
R And D Expense:1,126,000.00
Sga Expense:1,348,000.00
Income Tax Expense:$0.00
Interest Expense:385.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$11.45M
Current Assets:$3.18M
Ppe Net:1,727,000.00
Goodwill:1,731,000.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:4,195,000.00
Current Liabilities:4,195,000.00
Long Term Debt:$0.00
Short Term Debt:$355.00K

Equity & Capital (3)

Equity:$7.25M
Retained Earnings:-$84.89M
Common Stock:291,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:880,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:765,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$2.77M-$2.77M

Investment Activities (1)

Investing Cash Flow:$1.70M

Financing Activities (3)

Financing Cash Flow:$2.63M
Dividends Paid Ttm:2,076,180.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:1,750,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:55,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$2.16

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.72

Book Value & Capital (2)

Book Value Per Share:$1.89
Cash Per Share:0.57

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:91.3%
Fundamental Growth Rate (g):-32.5%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:NLSP
Company Name:NewcelX Ltd.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.84M
Shares Outstanding Basic:3.84M
Shares Outstanding Diluted:3.84M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-07 20:03:41 UTC
Data Timestamp:2026-06-07T20:03:41.047226
Scroll to Top